[Peripheral vascular diseases and generalized scleroderma treated with mydocalm].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001775:Blood Circulation / Q000187:drug effects; D001808:Blood Vessels / Q000187:drug effects; D006801:Humans; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D011427:Propiophenones / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D014652:Vascular Diseases / Q000188:drug therapy*
D009125:Muscle Relaxants, Central; D010880:Piperidines; D011427:Propiophenones
Wpływ leczenia mydokalmem na schorzenia naczyń obwodowych i uogólnionatwardzine skóry.